Table 2.
Subsequent outcomes based on achieving or failing PFS24 in subgroups.
| Outcomes from time of achieving PFS24 | Outcomes from time of failing PFS24 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of | 5-year OS | SMR | No. of | 3-year OS | SMR | |||||
| Subgroups | patients | % (95%CI) | P | (95% CI) | Pa | patients | % (95%CI) | P | (95% CI) | Pa |
| Sex | 0.564 | 0.229 | ||||||||
| Male | 708 | 91.2 (87.7–94.9) | 1.5 (1.1–2.1) | 0.015 | 242 | 22.2 (17.0–29.1) | 66.9 (57.6–77.8) | <0.001 | ||
| Female | 306 | 94.6 (91.7–97.6) | 3.8 (2.2–6.5) | <0.001 | 106 | 29.0 (20.9–40.2) | 85.3 (67.5–107.9) | <0.001 | ||
| Age (years) | 0.050 | 0.856 | ||||||||
| ≤60 | 883 | 93.3 (90.7–96.0) | 3.7 (2.7–5.0) | <0.001 | 305 | 23.9 (19.1–30.0) | 158.2 (138.2–180.9) | <0.001 | ||
| >60 | 131 | 84.8 (75.1–95.9) | 0.6 (0.3–1.1) | 0.119 | 43 | 28.6 (17.4–47.0) | 13.9 (9.6–20.1) | <0.001 | ||
| Primary site | <0.001 | 0.126 | ||||||||
| UADT | 982 | 92.7 (90.1–95.4) | 1.6 (1.2–2.1) | 0.002 | 315 | 24.4 (19.7–30.3) | 74.4 (65.2–84.9) | <0.001 | ||
| Extra-UADT | 32 | 76.2 (60.2–96.5) | 9.2 (4.1–20.5) | <0.001 | 33 | 21.6 (9.4–49.6) | 48.9 (31.2–76.7) | <0.001 | ||
| Regional lymph nodes | 0.030 | 0.210 | ||||||||
| Yes | 338 | 92.0 (88.4–95.7) | 3.7 (2.4–5.6) | <0.001 | 159 | 20.4 (14.5–28.9) | 106.4 (88.5–127.8) | <0.001 | ||
| No | 676 | 92.7 (89.5–96.0) | 1.3 (0.9–1.8) | 0.222 | 189 | 27.6 (21.3–35.7) | 55.1 (46.2–65.6) | <0.001 | ||
| Distant lymph nodes | 0.005 | 0.944 | ||||||||
| Yes | 31 | 85.8 (73.8–99.7) | 6.6 (2.5–17.6) | <0.001 | 30 | 11.6 (3.4–40.0) | 106.2 (69.9–161.3) | <0.001 | ||
| No | 983 | 92.5 (89.8–95.2) | 1.7 (1.2–2.2) | <0.001 | 318 | 25.4 (20.6–31.3) | 69.1 (60.6–79.0) | <0.001 | ||
| Primary tumor invasion | 0.908 | 0.006 | ||||||||
| Yes | 524 | 93.6 (90.9–96.3) | 1.9 (1.3–2.9) | <0.001 | 220 | 21.0 (15.7–28.0) | 116.0 (99.3–135.5) | <0.001 | ||
| No | 490 | 91.0 (86.8–95.5) | 1.6 (1.1–2.4) | 0.015 | 128 | 30.2 (22.4–40.6) | 40.7 (32.7–50.6) | <0.001 | ||
| B symptoms | 0.472 | 0.659 | ||||||||
| Yes | 380 | 90.8 (85.9–96.0) | 2.6 (1.7–3.9) | <0.001 | 146 | 24.2 (17.5–33.5) | 100.2 (82.2–122.2) | <0.001 | ||
| No | 634 | 93.1 (90.2–96.0) | 1.5 (1.0–2.1) | 0.045 | 202 | 24.3 (18.5–32.0) | 59.6 (50.6–70.3) | <0.001 | ||
| Elevated LDH | 0.053 | 0.061 | ||||||||
| Yes | 229 | 92.2 (88.5–96.1) | 3.0 (1.8–4.8) | <0.001 | 113 | 16.5 (9.9–27.4) | 88.0 (71.1–108.8) | <0.001 | ||
| No | 785 | 92.3 (89.2–95.5) | 1.5 (1.1–2.1) | 0.020 | 235 | 27.7 (22.1–34.8) | 64.7 (55.3–75.8) | <0.001 | ||
| ECOG score | <0.001 | <0.001 | ||||||||
| 0–1 | 979 | 93.3 (91.0–95.6) | 1.7 (1.2–2.3) | <0.001 | 323 | 26.2 (21.3–32.1) | 66.9 (58.6–76.4) | <0.001 | ||
| ≥2 | 35 | 56.2 (24.9–100) | 3.0 (1.3–6.6) | 0.008 | 25 | 0 | 216.9 (142.8–329.4) | <0.001 | ||
| Ann Arbor stage | <0.001 | 0.753 | ||||||||
| I–II | 950 | 92.9 (90.2–95.6) | 1.5 (1.1–2.1) | 0.009 | 289 | 25.8 (20.9–32.0) | 67.3 (58.5–77.2) | <0.001 | ||
| III–IV | 64 | 83.1 (73.4–94.2)b | 9.6 (5.0–18.4) | <0.001 | 59 | 13.7 (5.9–31.8) | 103.6 (76.0–141.3) | <0.001 | ||
| KPI | 0.006 | 0.492 | ||||||||
| Group 1 | 367 | 94.1 (90.5–97.9) | 1.9 (0.5–1.5) | 0.644 | 83 | 27.3 (18.9–39.5) | 48.0 (37.1–62.1) | <0.001 | ||
| Group 2 | 375 | 90.1 (84.7–95.8) | 2.2 (1.4–3.4) | <0.001 | 124 | 29.4 (21.6–40.1) | 60.6 (48.7–75.5) | <0.001 | ||
| Group 3 | 192 | 95.8 (92.8–98.9) | 2.0 (1.0–3.9) | 0.056 | 81 | 17.4 (11.1–35.4) | 131.7 (102.1–170.0) | <0.001 | ||
| Group 4 | 80 | 86.5 (78.5–95.3) | 9.3 (4.9–17.9) | <0.001 | 60 | 17.0 (8.8–32.7) | 111.9 (83.0–150.8) | <0.001 | ||
| PINK | <0.001 | 0.928 | ||||||||
| Low risk | 798 | 94.5 (91.9–97.2) | 2.6 (1.8–3.9) | <0.001 | 234 | 26.0 (20.5–32.9) | 145.8 (125.1–170.0) | <0.001 | ||
| Intermediate risk | 172 | 83.9 (75.6–93.0) | 1.0 (0.7–1.7) | 0.839 | 69 | 22.8 (13.7–37.9) | 27.5 (20.7–36.6) | <0.001 | ||
| High risk | 44 | 85.4 (75.2–96.9) | 5.0 (2.2–11.1) | <0.001 | 45 | 14.3 (5.7 –36.3) | 56.2 (39.3–80.4) | <0.001 | ||
| NRI | 0.001 | 0.186 | ||||||||
| Low risk | 285 | 94.5 (90.6–98.7) | 2.3 (1.2–4.4) | 0.012 | 48 | 32.5 (21.2–49.8) | 99.2 (70.5–139.6) | <0.001 | ||
| Intermediate-low risk | 314 | 92.8 (87.8–98.2) | 1.0 (0.5–1.8) | 0.978 | 101 | 27.2 (19.1–38.9) | 47.7 (37.4–60.94) | <0.001 | ||
| Intermediate-high risk | 260 | 90.8 (85.9–96.0) | 2.0 (1.3–3.2) | 0.003 | 95 | 29.2 (20.8–41.1) | 77.2 (60.4–98.6) | <0.001 | ||
| High risk | 110 | 92.5 (87.2–98.1) | 2.4 (1.2–5.1) | 0.019 | 69 | 13.9 (6.4–29.9) | 116.6 (88.4–153.9) | <0.001 | ||
| Very high risk | 45 | 85.1 (74.8–96.8) | 2.9 (1.3–6.5) | 0.008 | 35 | 13.4 (5.1–35.6)c | 68.6 (47.4–99.4) | <0.001 | ||
PFS24 progression-free survival at 24 months; SMR standardized mortality ratio; OS overall survival; UADT upper aerodigestive tract; LDH lactate dehydrogenase; ECOG Eastern Cooperative Oncology Group.
aCompared with the age- and sex-matched general Chinese population.
b3-year OS rate from PFS24.
c2-year OS rate from progression.